Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of intrathecal tominersen in manifest Huntington's disease
NL-OMON55873Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Aug 2019
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tominersen in Huntington disease (HD) (3 arms), sponsored by Roche. Primary endpoints: Change from baseline in composite Unified Huntington's Disease Rating Scale and Change from baseline in cerebrospinal fluid mutant huntingtin protein. Started Aug 2019; status: active, not recruiting.
02
Drugs
tominersen
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on NL-OMON55873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55873.